🫀 Mechanical Circulatory Support/ECMO Indications
This tool guides selection of mechanical circulatory support (IABP, Impella, VA-ECMO, or RV assist) in cardiogenic shock by the type of failure, integrating recent randomized trials and 2023 ESC / 2025 ACC/AHA recommendations.
Clinical takeaway
No temporary MCS device holds a Class I recommendation; benefit is limited to selected subgroups, so device choice should be individualized by failure type and center experience. (original synthesis · not guideline verbatim)
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use at the bedside in cardiogenic shock to match the device to the failure pattern — isolated LV, refractory/arrest, RV/biventricular, or mechanical complication — while emphasizing early recognition, referral to experienced centers, and a planned weaning/escalation strategy.
How it works
Decision logic by failure type: isolated LV → Impella (STEMI severe/refractory, IIa); refractory/arrest/cardiopulmonary failure → VA-ECMO ± LV unloading (against routine use; IIb for refractory); RV/biventricular → RV assist or VA-ECMO; mechanical complication → IABP bridge.
Key points
- No temporary MCS device holds a Class I recommendation; benefit is limited to selected subgroups, so device choice should be individualized by failure type and center experience. (original synthesis · not guideline verbatim)
- DanGer Shock (2024) supported Impella in STEMI-CS (upgraded to IIa) at a cost of more bleeding, hemolysis, AKI, and limb ischemia.
- ECLS-SHOCK (2023) found routine early VA-ECMO did not reduce AMI-CS mortality and increased complications; VA-ECMO often needs LV unloading.
References
- Møller JE, et al. (DanGer Shock). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med 2024.
- Thiele H, et al. (ECLS-SHOCK). Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N Engl J Med 2023.
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Type of failure/shock | Isolated LV failure (e.g. STEMI-related severe/refractory CS) |
|---|
→MCS recommendationImpella (micro-axial flow pump)
- Recommended direction：Isolated LV failure, STEMI-related severe/refractory CS: DanGer Shock (2024) showed Impella CP improves survival in STEMI-CS (but with more bleeding/hemolysis/AKI/limb ischemia) → 2025 ACC/AHA upgraded to IIa (STEMI severe/refractory shock, experienced centers). IABP is not recommended routinely (IABP-SHOCK II neutral, Class III). Contraindications: mechanical aortic valve, severe AS, LV thrombus, severe peripheral vascular disease, VSD
- Overall principle：At present no tMCS device has a Class I recommendation; benefit is limited to selected subgroups. Emphasize early recognition (SCAI stage + lactate + neurologic status), timely referral to experienced centers, individualized selection by failure type and center experience, and planning a weaning/escalation strategy
- Basis：IABP-SHOCK II 2012; ECLS-SHOCK 2023; DanGer Shock 2024; 2023 ESC ACS guidelines; 2025 ACC/AHA ACS guidelines
| Type of failure/shock | Mechanical complication (acute MR/VSD) needing a bridge |
|---|
→MCS recommendationIABP as a bridge
- Recommended direction：Mechanical complication (acute mitral regurgitation/ventricular septal rupture): IABP reduces afterload and improves coronary perfusion as a bridge before surgery/intervention; pursue definitive surgical/interventional repair as soon as possible
- Overall principle：At present no tMCS device has a Class I recommendation; benefit is limited to selected subgroups. Emphasize early recognition (SCAI stage + lactate + neurologic status), timely referral to experienced centers, individualized selection by failure type and center experience, and planning a weaning/escalation strategy
- Basis：IABP-SHOCK II 2012; ECLS-SHOCK 2023; DanGer Shock 2024; 2023 ESC ACS guidelines; 2025 ACC/AHA ACS guidelines
Frequently asked questions
- What is Mechanical Circulatory Support/ECMO Indications?
- This tool guides selection of mechanical circulatory support (IABP, Impella, VA-ECMO, or RV assist) in cardiogenic shock by the type of failure, integrating recent randomized trials and 2023 ESC / 2025 ACC/AHA recommendations.
- How is Mechanical Circulatory Support/ECMO Indications calculated? What is the core formula?
- Decision logic by failure type: isolated LV → Impella (STEMI severe/refractory, IIa); refractory/arrest/cardiopulmonary failure → VA-ECMO ± LV unloading (against routine use; IIb for refractory); RV/biventricular → RV assist or VA-ECMO; mechanical complication → IABP bridge.
- When is Mechanical Circulatory Support/ECMO Indications used?
- Use at the bedside in cardiogenic shock to match the device to the failure pattern — isolated LV, refractory/arrest, RV/biventricular, or mechanical complication — while emphasizing early recognition, referral to experienced centers, and a planned weaning/escalation strategy.
- What are the key clinical points for Mechanical Circulatory Support/ECMO Indications?
- No temporary MCS device holds a Class I recommendation; benefit is limited to selected subgroups, so device choice should be individualized by failure type and center experience. (original synthesis · not guideline verbatim) DanGer Shock (2024) supported Impella in STEMI-CS (upgraded to IIa) at a cost of more bleeding, hemolysis, AKI, and limb ischemia. ECLS-SHOCK (2023) found routine early VA-ECMO did not reduce AMI-CS mortality and increased complications; VA-ECMO often needs LV unloading.
- What are the limits and cautions when using Mechanical Circulatory Support/ECMO Indications?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Mechanical Circulatory Support/ECMO Indications calculated in practice? Can you show a worked example?
- Inputs: Type of failure/shock Isolated LV failure (e.g. STEMI-related severe/refractory CS) → Result: MCS recommendation Impella (micro-axial flow pump)（Recommended direction: Isolated LV failure, STEMI-related severe/refractory CS: DanGer Shock (2024) showed Impella CP improves survival in STEMI-CS (but with more bleeding/hemolysis/AKI/limb ischemia) → 2025 ACC/AHA upgraded to IIa (STEMI severe/refractory shock, experienced centers). IABP is not recommended routinely (IABP-SHOCK II neutral, Class III). Contraindications: mechanical aortic valve, severe AS, LV thrombus, severe peripheral vascular disease, VSD, Overall principle: At present no tMCS device has a Class I recommendation; benefit is limited to selected subgroups. Emphasize early recognition (SCAI stage + lactate + neurologic status), timely referral to experienced centers, individualized selection by failure type and center experience, and planning a weaning/escalation strategy, Basis: IABP-SHOCK II 2012; ECLS-SHOCK 2023; DanGer Shock 2024; 2023 ESC ACS guidelines; 2025 ACC/AHA ACS guidelines） Inputs: Type of failure/shock Mechanical complication (acute MR/VSD) needing a bridge → Result: MCS recommendation IABP as a bridge（Recommended direction: Mechanical complication (acute mitral regurgitation/ventricular septal rupture): IABP reduces afterload and improves coronary perfusion as a bridge before surgery/intervention; pursue definitive surgical/interventional repair as soon as possible, Overall principle: At present no tMCS device has a Class I recommendation; benefit is limited to selected subgroups. Emphasize early recognition (SCAI stage + lactate + neurologic status), timely referral to experienced centers, individualized selection by failure type and center experience, and planning a weaning/escalation strategy, Basis: IABP-SHOCK II 2012; ECLS-SHOCK 2023; DanGer Shock 2024; 2023 ESC ACS guidelines; 2025 ACC/AHA ACS guidelines）